Quotables
"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6866852 | Recombinant herpesvirus of turkeys and use thereof The present invention provides a recombinant herpesvirus of turkeys modified by the presence of cDNA encoding the F protein of Newcastle disease virus under the control of a promoter. The poultry vaccine consisting of the recombinant herpesvirus of turkeys of the pr... | 03/15/2005 |
| 6861059 | Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic age... | 03/01/2005 |
| 6855809 | Methods for the simultaneous detection of HCV antigens and HCV antibodies The subject invention relates to methods for the simultaneous detection of Hepatitis C Virus (HCV) antigens as well as antibodies produced in response to HCV antigens. Furthermore, the subject invention allows one to detect antigens in the early, acute stage of infe... | 02/15/2005 |
| 6855492 | Use of microparticles combined with submicron oil-in-water emulsions Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submi... | 02/15/2005 |
| 6852324 | Immunization for ebola virus infection Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes th... | 02/08/2005 |
| 6846652 | Viral vectors having enhanced effectiveness with reduced virulence The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising ... | 01/25/2005 |
| 6846905 | Antigen constructs useful in the detection and differentiation of antibodies to HIV Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constr... | 01/25/2005 |
| 6843997 | Variant varicella-zoster viruses and methods of use The present invention provides methods directed to detecting antibodies that specifically bind to a varicella zoster polypeptide, detecting the presence of a varicella zoster virus in an animal, diagnosing a disease caused by varicella zoster virus, and detecting a ... | 01/18/2005 |
| 6843992 | Immuno-reactive peptide CTL epitopes of human cytomegalovirus The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) inf... | 01/18/2005 |
| 6841157 | Production of chimeric human papillomavirus This invention relates to infectious chimeric papillomaviruses, and especially those where the early genes are from human papillomavirus (HPV) 18, and the late genes are from another HPV. Also presented are methods of culturing the virus in raft cell cultures, and t... | 01/11/2005 |
| 6841374 | Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same The present invention provides a novel inactivated virus particle and a reinforced immunogen which have a reinforced titer about twice to about 10 times that of a conventional vaccine, as well as a method for producing the same. The inactivated virus particle is pro... | 01/11/2005 |
| 6838084 | Cytotoxic T-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL (SEQ ID NO: 1), RLVWACVGV (SEQ ID NO: 2), HLFNRAGTV (SEQ ID NO: 3), YLRREQMFV (SEQ ID NO: 4), TLQANKSEV (SEQ ID NO: 5), ILEDWNFGL (SEQ ID NO: 6), SLWLPSEATVYL (S... | 01/04/2005 |
| 6830748 | Recombinant RSV virus expression systems and vaccines The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant ... | 12/14/2004 |
| 6827939 | Peptide having an affinity for gp120 The peptide in this invention is a peptide having affinity to gp120 represented by H-A1-A2-A3-A4-A5-R (SEQ ID No. 1) Formula (1) (in the formula, H means hydrogen, A... | 12/07/2004 |
| 6827933 | Immunogenic compositions of human papillomavirus and sera produced therefrom A purified human papillomavirus gene selected from the group consisting of E1, E6-E7, L1, and L2, wherein said human papillomavirus is selected from the group consisting of HPV-2d, HPV-10b, HPV-14a, HPV-14b, HPV-15, HPV-17a, HPV-17b, HPV-19, HPV-20, HPV-21, HPV-22, ... | 12/07/2004 |
| 6824784 | Cold-adapted equine influenza viruses The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at ... | 11/30/2004 |
| 6821519 | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection Compounds and methods for the diagnosis and treatment of HSV infection are provided. The compounds comprise polypeptides that contain at least one antigenic portion of an HSV polypeptide and DNA sequences encoding such polypeptides. Pharmaceutical compositions and v... | 11/23/2004 |
| 6818219 | Reagent for detecting and monitoring viral infections The invention concerns a reagent for diagnosing an infection caused by a virus, characterized in that it comprises essentially a mixture consisting of (1) an immunodominant fragment of a protein of said virus comprising not more than 60 aminoacids, preferably betwee... | 11/16/2004 |
| 6811784 | Recombinant parainfluenza virus expression system and vaccines The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or... | 11/02/2004 |
| 6808877 | Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection The present invention relates to the discovery of molecules that inhibit viral infection and promote a host immune response to a pathogen. More specifically, the invention disclosed herein concerns molecules that interact with a FPR class receptor, inhibit HIV infec... | 10/26/2004 |
| 6805867 | Bovine rotavirus genes The present invention provides the genes encoding the following BRV proteins: for group A, the VP4 and VP7 proteins of the Indiana (IND) strain, and the VP7 protein of the 2292B strain; for group B, the VP7 protein of the WD653 strain; for group C, the VP4 and VP7 p... | 10/19/2004 |
| 6803041 | Equine herpesvirus vaccine A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically uns... | 10/12/2004 |
| 6797491 | Human papilloma virus treatment Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disc... | 09/28/2004 |
| 6797276 | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a ystemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or ch... | 09/28/2004 |
| 6793926 | Methods for production of a recombinant adeno-associated virus This invention relates to novel nonmammalian carrier vectors and viruses useful in the production of high titers of recombinant viruses which may contain foreign DNA inserts or which may be point-mutated or deleted viruses, and methods of producing those viruses. Th... | 09/21/2004 |
| 6794174 | Full-length infectious cDNA clones of tick borne flavivirus Embodiments described herein include full-length infectious cDNA clones of Langat tick-borne flavivirus. ... | 09/21/2004 |
| 6790446 | Campylobacter vaccine The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonization in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of... | 09/14/2004 |
| 6787137 | Campylobacter vaccine The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonisation in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of... | 09/07/2004 |
| 6783763 | Polyepitopic proteinic fragments of the E6 and E7 HPV proteins, production and use thereof in vaccines Polyepitopic fragments of the E6 or E7 protein of HPV comprise a peptide sequence of about 15 to 30 amino acids. This peptide sequence contains amino acid sequences of at least 3 different epitopes binding stably to HLA molecules of identical or different type, when... | 08/31/2004 |
| 6777247 | Nervous necrosis virus protein The invention relates to a new RNA polymerase isolated from a Nervous Necrosis Virus. ... | 08/17/2004 |
| 6773908 | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) The present invention provides an isolated DNA sequence encoding, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndro... | 08/10/2004 |
| 6773710 | Recombinant canine distemper virus vaccine against canine distemper and leishmaniasis The present invention provides a vaccine against canine distemper and leishmaniasis by constructing a recombinant canine distemper virus containing a gene encoding a protein associated with protection against Leishmania protozoa infection inserted into the canine di... | 08/10/2004 |
| 6773709 | Chicken embryo lethal (CELO) virus A CELO virus obtained by in vitro manipulation of a plasmid-cloned CELO virus DNA is suitable for the production of vectors for gene therapy and as a vaccine against infectious diseases in humans and animals, particularly birds. ... | 08/10/2004 |
| 6770283 | DNA expression systems based on alphaviruses The disclosure describes recombinant alphavirus RNA molecules and expression of heterologous proteins therefrom in animal cells. Recombinant alphaviruses of the present invention, when made to express an antigenic protein, can be administered as vaccines. ... | 08/03/2004 |
| 6770282 | Cationic lipid-mediated enhancement of nucleic acid immunization of cats The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cati... | 08/03/2004 |
| 6764685 | Recombinant parainfluenza virus expression systems and vaccines The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or... | 07/20/2004 |
| 6764684 | Avian herpesvirus-based recombinant infectious bursal disease vaccine The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvi... | 07/20/2004 |
| 6759050 | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freez... | 07/06/2004 |
| 6756040 | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed onto aluminum phosphate. The invention also relates to a multivalent vaccines, that is a vaccine for the amelioratio... | 06/29/2004 |
| 6750043 | Viral vectors having reduced virulence The present invention provides recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA. Compositions comprising the recombinant vaccinia virus and methods of use thereo... | 06/15/2004 |
